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rus were unaffected in minocycline-treated mice.  Conclu-
sions: These results suggest a role for microglia in A  -related 
functional deficits and in suppressing the survival of new 
neurons, and show that modulation of microglial function 
with minocycline can protect hippocampal neurogenesis in 
the presence of A  pathology. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Characteristic hallmarks of Alzheimer’s disease (AD) 
include the deposition of A  , formation of neurofibril-
lary tangles, neurodegeneration along with signs of in-
creased inflammatory responses  [1, 2] . Activated micro-
glia and reactive astrocytes, often associated with A  de-
posits, not only produce cytokines, chemokines, reactive 
oxygen species and neurotoxic factors, but may also con-
tribute to neurotrophic activities  [3–5] . In a transgenic 
mouse model of AD expressing amyloid precursor pro-
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 Abstract 
 Background: Activated microglia with macrophage-like 
functions invade and surround   -amyloid (A  ) plaques in Alz-
heimer’s disease (AD), possibly contributing to the turnover 
of A  , but they can also secrete proinflammatory factors that 
may be involved in the pathogenesis of AD. Microglia are 
known to modulate adult hippocampal neurogenesis.  Ob-
jectives/Methods:  To determine the role of microglia on 
neurogenesis in brains with A  pathology, we inhibited mi-
croglial activation with the tetracycline derivative minocy-
cline in doubly transgenic mice expressing mutant human 
amyloid precursor protein (APP) and mutant human prese-
nilin-1 (PS1).  Results: Minocycline increased the survival of 
new dentate granule cells in APP/PS1 mice indicated by
more BrdU+/NeuN+ cells as compared to vehicle-treated 
transgenic littermates, accompanied by improved behavior-
al performance in a hippocampus-dependent learning task. 
Both brain levels of A  and A  -related morphological defi-
cits in the new neurons labeled with GFP-expressing retrovi-
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tein (APP)/mutant human presenilin-1 (PS1) mutations, 
microglia react to A  pathology with a sequence of dy-
namic changes  [6] . During the onset of A  plaque deposi-
tion, activated CD11b+ (cluster of differentiation 11B, 
complement receptor, CR3, or Macrophage-1 antigen, 
MAC-1) microglia are present in the vicinity of A  
plaques, followed by increased expression of CD45 dur-
ing progressing pathology, and by increased expression of 
MHC-II at late-stage of A  pathology [ 4 ; B. Biscaro, un-
publ. data]. However, experimental evidence suggests 
that neither the formation nor the maintenance of A  or 
the associated neuritic dystrophy requires the presence of 
microglia in transgenic mice  [7] .
 Neurogenesis, i.e. the generation of neurons from 
stem/progenitor cells, includes proliferation, fate specifi-
cation, neuronal maturation and survival, and ultimately 
synaptic integration of newborn neurons into functional 
neuronal circuits  [8, 9] . In the adult mammalian brain, 
progenitor cells are located in the dentate gyrus subgran-
ular zone (SGZ) of the hippocampus, as well as in the 
subventricular zone, lining the lateral ventricles. Prolif-
eration and differentiation of neural stem cells are finely 
tuned by physiological stimuli, and neurogenesis is sensi-
tive to pathological disease states affecting the microen-
vironment of the neural stem cell niches  [9–11] . Glial cells 
influence these stem cell niches with a variety of secre-
tory factors, and their effects on neurogenesis can be ei-
ther damaging or supportive depending on the factors 
involved  [12] .
 Minocycline is a tetracycline derivative with anti-in-
flammatory properties; it crosses the blood-brain barrier 
rapidly and inhibits microglia within the CNS. We have 
previously shown that minocycline restores neurogenesis 
after inflammation provoked by lipopolysaccharide in-
fusion  [13] . Minocycline is known to inhibit inflamma-
tion and microgliosis in several models of neurodegen-
erative disease including AD  [14–19] , but it is unknown 
how this relates to adult neurogenesis in the mouse mod-
els. The aim of the present study was to determine the 
action of microglia on neurogenesis in transgenic APP/
PS1 mice with pre-existing A  pathology. While mino-
cycline failed to affect reactive astrocytes, it reduced mi-
croglia in the dentate gyrus, decreased inducible nitric 
oxide synthase (iNOS) protein levels in brain homoge-
nates as well as the reactivity of A  plaque-associated 
CD11b+ microglia in the hippocampus. Minocycline also 
increased the numbers of new neurons in the granule cell 
layer (GCL) without reducing cerebral A  . Downregula-
tion of proinflammatory and upregulation of anti-in-
flammatory cytokines, as well as improved recognition 
memory, were associated with the minocycline adminis-
tration to transgenic AD mice. Together, these results 
suggest that microglia are involved in the inhibition of 
adult neurogenesis during brain   -amyloidosis.
 Materials and Methods 
 Transgenic Mice 
 Heterozygous doubly transgenic mice expressing both human 
mutant APP (Tg 2576)  [20] and PS1 (mutation: M146L) were gen-
erated by crossing heterozygous APP (C57BL6/J  ! FVB/N  ! 
SJL/J background) with PS1 mice (Swiss Webster  ! B6D2F1 
background). Genotypes were determined by PCR. Both males 
and females were housed in standard cages with females in groups 
of 2–4 and males single-caged under 12-hour light/dark condi-
tions with ad libitum access to water and food. A total of 30 mice 
were included in the study (F1 generation, with the mixed back-
ground strain resulting from the breeding scheme described 
above), 15 of which were injected with GFP-expressing retroviral 
vector; n = 5 (3 females and 2 males) non-transgenic (non-tg) with 
vehicle treatment, which received retroviral vector infusion into 
the dentate gyrus; n = 5 (3 females and 2 males) non-tg with mi-
nocycline treatment; n = 10 (5 females and 5 males) APP/PS1 with 
vehicle treatment, of which 5 (3 females and 2 males) mice re-
ceived retroviral vector infusion into the dentate gyrus; n = 10 (5 
females and 5 males) APP/PS1 with minocycline treatment, of 
which 5 (2 females and 3 males) mice received retroviral vector 
infusion into the dentate gyrus. All experimental procedures fol-
lowed guidelines set by the Swiss veterinary cantonal office for the 
use and care of laboratory animals (License No. 48/08).
 Minocycline Treatment 
 Minocycline (Sigma-Aldrich, St. Louis, Mo., USA) was freshly 
prepared as a 5 mg/ml stock solution in dextrose 5% water (D5W, 
vehicle), pH 7.4, every 3 days. APP/PS1 mice as well as non-tg con-
trols were 11 weeks old at the beginning of the experiment. APP/
PS1 received minocycline (50 mg/kg, i.p.), whereas control groups 
APP/PS1 and non-tg received vehicle (10   l/g body weight, i.p.) 
twice daily for the first 2 days and once daily for the next 5 days 
until stereotaxic surgery. Following retroviral vector injections, 
mice received halved dose of minocycline (25 mg/kg, i.p.) or ve-
hicle once daily for the next 5 weeks. Animal body weights were 
measured weekly and the injection volumes were modified ac-
cording to the detected changes. Two days before transcardial 
perfusion, all groups were subjected to behavioral testing as de-
scribed below. Mice were perfused 24 h after the last injection and 
blood was withdrawn by heart puncture after deep anesthesia 
with ketamine/xylazine directly before perfusion, and separated 
from erythrocytes by centrifugation.
 Bromodeoxyuridine Labeling 
 Starting the day of the retroviral vector infusion, mice were 
injected twice daily for three days with BrdU (50 mg/kg, i.p., dis-
solved in potassium-phosphate-buffered saline, KPBS) for label-
ing of mitotic cells  [21] . Mice were sacrificed 5 weeks after the 
BrdU injections.
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 Retrovirus-Mediated Labeling of New Hippocampal Neurons 
 An oncoretroviral vector derived from the Moloney sarcoma 
virus and expressing GFP under control of the Rous sarcoma vi-
rus promoter (MolRG) was used. The retroviral vector was pro-
duced and stereotactically injected into the dentate gyrus as pre-
viously described  [22] .
 Learning and Memory Assessments 
 After 6 weeks’ treatment with minocycline and 5 weeks after 
BrdU administration, all mice were moved to an inverted light 
cycle room 1 day after stereotaxic surgery and, on the day of the 
experiment, they were habituated to the testing room for at least 
1 h. Behavioral analysis was performed by an observer blinded to 
the experimental groups. Because the performance of mice sub-
jected to retrovirus perfusion was comparable to that of mice that 
did not undergo surgery, the data were pooled within the same 
group of treatment.
 Spatial Working Memory  was assessed in a Y-maze task 2 days 
before perfusion. The total number of arm entries and the se-
quence of entries in the Y-maze were manually recorded during a 
5-min session. Data were analyzed to determine the number of 
arm entries without repetition. Success in this test is indicated by 
a high rate of alternation indicating that the animals can remem-
ber which arm was entered last. Results are presented as percent-
age of alternations, e.g. the ratio of actual divided with possible 
alternations (total number of arm entries –2) times 100. The per-
formance of the animals in the maze was also digitally recorded 
with a computer-aided video analysis system (EthoVision, Nol-
dus, Bayern, Germany).
 Recognition Memory  was tested in a hippocampus-dependent 
object recognition task  [23] . On day 1, mice were habituated to the 
empty testing cage (20 min). The testing cage was an opaque plas-
tic chamber (25  ! 40  ! 15 cm) with bedding material from the 
home cages of the animals. In this way, mice in this olfactory-
saturated environment extensively explore the objects rather than 
primarily examine the apparatus. On day 2, the animals were set 
into the testing chamber now containing an object, and they were 
allowed to explore the object for 5 min (‘familiarization phase’). 
After a 20-min delay, during which the mice returned to their 
home cages, the animals were replaced into the testing chamber 
that now contained the familiar object (object A) and a new object 
(object B) (‘novelty phase’). The mice were given 5 min to explore 
the familiar and new objects during the second exposure. The fa-
miliarization and testing phases were filmed with a digital video 
camera for off-line analysis (EthoVision) and the times spent ex-
ploring familiar and novel object during the novelty phase were 
scored. ‘Exploration’ of objects A and/or B was defined as ap-
proaching the object nose-first within 2–4 cm. A recognition in-
dex, calculated for each mouse, was expressed as the ratio ( T B 
 * 100)/( T A +  T B), where  T A and  T B are the time spent during the 
second exposure on object A and object B, respectively. All of the 
objects used were made of plastic or wood and did not differ in 
overall size but differed in shape and color. During the testing, 2 
non-tg mice treated with minocycline had to be excluded because 
of stereotypic behavior, reducing the number of animals in this 
group to 3.
 Tissue Preparation 
 Mice that received retrovirus injection were anesthetized with 
ketamine/xylaxine, and were transcardially perfused with 50 ml 
PBS, followed by 100 ml of ice-cold 4% paraformaldehyde in
0.1  M PBS, pH 7.4. Brains were removed, post-fixed overnight in 
the same medium, and put in 20% sucrose in 0.1  M phosphate buff-
er for 24 h. Systemically random coronal sections (40-  m thick) 
were cut on a sliding microtome, with an interval of 320   m be-
tween consecutive sections, and stored in cryoprotective solution.
 Mice that did not receive retrovirus injection were anesthe-
tized with ketamine/xylaxine, and were transcardially perfused 
with 150 ml of ice-cold PBS. Brains were removed and dissected 
through the midsagital plane. One hemisphere was either further 
dissected into cortex and hippocampus and snap-frozen in liquid 
nitrogen and stored at –80  °  C, or fixed with 4% paraformaldehyde 
for 24 h at 4  °  C and processed as described above.
 Protein Extraction 
 Cortices and hippocampi were homogenized in 10 tissue vol-
umes (w/v) of 50 m M Tris-HCl, 150 m M NaCl, pH 7.5, containing 
complete protease inhibitor cocktail (Roche, Basel, Switzerland) 
with Teflon-glass homogenizer (40 strokes) and subsequently 
centrifuged at 14,000  g  for 50 min at 4 °   C (soluble fraction). The 
supernatants were collected, and, prior to storage at –80   °   C, the 
protein concentrations were determined using the BCA Protein 
Assay (Pierce Biotechnology, Rockford, Ill., USA). Pellets were 
further processed with 70% formic acid (FA) to solubilize A  
from the aggregated A  plaques, and spun at 100,000  g  for 1 h at 
8  °  C (insoluble fraction). Aliquots of the 70% FA extraction super-
natant were lyophilized overnight in order to remove the acid, and 
stored at –80  °  C. Because at 4 months of age the accumulation of 
A  in the brain of APP/PS1 mice is most prominent in the cortex, 
extracts from cortices were used to evaluate A  and iNOS con-
centrations, whereas extracts from hippocampi were used to eval-
uate cytokine concentrations in the vicinity of the neurogenic 
niches.
 Immunohistochemistry 
 For epitope retrieval of BrdU and of the proliferating cell nu-
clear antigen (PCNA) (specifically expressed in early G1 and S 
phases of the cell cycle, thus identifying the actual number of di-
viding cells  [24] ), free-floating sections were denatured in 1  M HCl 
for 30 min at +60  °  C. Preincubation with 5% appropriate normal 
sera in KPBS containing 0.25% Triton-X-100 (T-KPBS) was car-
ried out for 1 h at room temperature. Primary antibodies were: 
rabbit anti-ionized calcium-binding adapter molecule 1 (Iba1) (a 
marker for microglia/macrophages,  [25] , 1: 1,000, Wako Chemi-
cals, Osaka, Japan); mouse anti-human A  (6E10) (1: 1,000, Co-
vance, Dedham, Mass., USA); rat anti-CD11b (CD11b expression 
is up-regulated in activated microglia, 1: 200, BD Pharmingen, 
San Jose, Calif., USA); guinea pig anti-glial fibrillary acidic pro-
tein (GFAP) (for identification of astrocytes, 1: 1,000, Advanced 
Immunochemicals, Long Beach, Calif., USA); rat anti-BrdU 
(1: 100, Oxford Biotec, Oxfordshire, UK); mouse anti-neuronal 
nuclei marker (NeuN) (1: 100, Chemicon, Temecula, Calif., USA); 
rabbit anti-S100  (a marker for astrocytes; 1: 5,000, SWANT, Bel-
linzona, Switzerland); goat anti-doublecortin (a marker for im-
mature neurons; 1: 400, Santa Cruz Biotechnology, Santa Cruz, 
Calif., USA), rabbit anti-Ki-67 (a marker for proliferating cells in 
G1, S and G2 phases; 1: 500, Biocare Medical, Concord, Calif., 
USA). Free-floating sections were incubated with the primary an-
tibody overnight at +4  °  C, in T-KPBS with 2% appropriate normal 
sera. Secondary antibodies for detection were Cy3-conjugated 
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donkey anti-rabbit/rat, FITC-conjugated goat anti-mouse/rabbit, 
Cy5-conjugated donkey anti-mouse/guinea pig with incubation 
for 2 h at room temperature in the dark. Rinsing in T-KPBS was 
carried out between the incubations. For single-staining with 
mouse anti-PCNA (1: 200, Santa Cruz Biotec), avidin-biotin-per-
oxidase complex (Elite ABC kit, Vector Laboratories, Burlingame, 
Calif., USA), 3,3  -diaminobenzidine and hydrogen peroxide were 
used. Chromogenic visualization included pretreatment with 
blocking of endogenous peroxidase activity with 3% H 2 O 2 and 
10% methanol. Sections were mounted on chrom-gelatin-coated 
microscope slides (Super-frost-plus; Menzel, Braunschweig, Ger-
many) and coverslipped with aqueous anti-fading mounting me-
dium (PVA-DABCO). Thioflavin-S (ThioS) staining for fibrillar 
A  was performed as described previously  [26] . Sections stained 
with ThioS were sequentially stained with 6E10 to detect the re-
maining, not-compact A  deposits. Control stainings included 
omission of the primary antibody and/or use of different tissues 
known to be positive for the specific antibody.
 Microscopic Analyses and Stereology 
 All measurements were performed by an observer blind to an-
imal identifications. Immunohistochemical stainings were ex-
amined with an Inverted Leica DM IRE2 fluorescence and light 
microscope. Numbers of immunoreactive cells were counted in 
4–5 consecutive sections, 320   m apart from each throughout the 
hippocampus (DV: –1.8 to –3.0) in the GCL, and within a 1-cell 
diameter below this region in the SGZ. Stereological estimations 
of the total number of BrdU+ in the SGZ/GCL as well as numbers 
of Iba1+ microglia and GFAP+ astrocytes in the dentate gyrus 
(GCL/SGZ + hilus) were performed using the optical fractionator 
method  [27, 28] with the support of newCAST software (Visio-
pharm, Copenhagen, Denmark) connected to a Leica DM4000B 
microscope ( ! 100 oil objective) with an Olympus DP71 color dig-
ital camera. For systematic sampling, the frame area was set to 
3,590   m 2 with a sampling interval of 226   m at the x and y lev-
el, and the optical disector constituting a 15-  m-thick fraction of 
the total section thickness (measuring an average of 25–27   m 
after processing). Neither the area for counting nor the thickness 
of the analyzed sections differed between groups, which allowed 
for comparisons of cell counts. Colocalization of up to 50 double-
stained BrdU+ cells with NeuN or S100  as well as PCNA+ with 
DCX+ cells was validated using a confocal scanning microscope 
(Leica TCS/SP2, Leica, Wetzlar, Germany) with argon laser 488, 
HeNE laser 568 and 633 excitation filters. Because CD11b was de-
tectable only surrounding the A  plaques, its immunoreactivity 
was evaluated by image analysis in the whole hippocampus (see 
below) rather than by cell counting due to the broader area con-
sidered and the spot-like appearance. A  deposition was also 
evaluated by image analysis of cortices and hippocampi, as de-
scribed below.
 Morphological Analysis of New GFP+ Mature Neurons 
 Detailed description of this analysis is provided elsewhere 
 [22] . Briefly, the dendritic lengths and branching of 5-week-old 
GFP+ new granular cells (n = 10 per group) were analyzed by us-
ing the Leica DM4000 microscope with a  ! 20 water objective and 
a digital zoom of 2 (1,024  ! 1,024 pixels). For spine density anal-
ysis, pictures of 2–3 dendritic segments 40   m long (n = 25 seg-
ments per group) per GFP+ cell analyzed were also taken using 
the Leica DM4000 microscope with a  ! 63 water objective and a 
digital zoom of 6 (512  ! 512 pixels). The fluorescence intensity of 
the labeled neurons was such that anti-GFP staining was unneces-
sary. After deconvolution using the open source Huygens remote 
manager (http://hrm.sourceforge.net/), 3D reconstructions of 
confocal images were performed with Imaris 6.1 (Bitplane, Zu-
rich, Switzerland). After 3D reconstructions, Scholl analysis and 
spine classification (stubby, long-thin and mushroom) were done 
using the aforementioned software and its MatLab extensions 
(ImarisXT).
 Image Analysis and Microglia Morphology 
 Before measuring areas with ImageJ (http://rsb.info.nih.gov/
ij/), all images were subjected to the following transformations: 
color pictures were first converted to grayscale images (8-bit) and 
then the resulting images were further adjusted to black and white 
by defining a grayscale cutoff point (threshold). All pictures were 
adjusted to the same threshold within the group of study, to allow 
comparison of the results. Quantification of diffuse plaque load 
(6E10 staining), compact plaque burden (ThioS), and activated 
microglia (CD11b) was reported as area fraction (% area), defined 
as the area positive for the staining in a constant and determined 
area of the cortex and hippocampus. The morphology of Iba1+ 
microglia in the dentate gyrus and septum was characterized as 
ramified, intermediate, amoeboid or round profile, as described 
elsewhere  [29] , and the percentage of the respective phenotype 
was calculated over the total number of Iba1+ cells considered 
(approximately 50 cells).
 Measurements of Mouse Cytokines 
 All samples were normalized to 400   g/ml before analysis. 
Levels of the pro-inflammatory cytokines interleukin-6 (IL-6) 
and tumor necrosis factor-  (TNF-  ) as well as level of the anti-
inflammatory IL-10 in hippocampal supernatants and plasma 
were measured using ELISA kits per manufacturer’s instructions 
(Invitrogen, Basel, Switzerland). Cytokines concentrations were 
normalized to total hippocampal protein concentration.
 Western Blotting 
 Tissue extracts were separated by SDS-PAGE using 10–20% 
Tricine gels (Invitrogen) and transferred onto nitrocellulose 
membranes. After an optional epitope retrieval and blocking in 
5% milk in Tris-buffered saline with 0.01% Tween-20, the mem-
branes were probed with biotinylated-6E10 (1: 500) antibody, and 
with rabbit anti-iNOS (1: 1,000, Millipore, Billerica, Mass., USA). 
Secondary antibody was streptavidin-conjugated peroxidase or 
anti-rabbit peroxidase (1: 10,000, Jackson Laboratories, Ben Har-
bor, ME). Immunopositive bands were visualized by chemilumi-
nescence (ECL, Amersham Biosciences) and subsequently quan-
tified by densitometric analysis of their intensity levels.   -Actin 
or GAPDH were used as loading control (1: 10,000, Sigma, St. Lou-
is, Mo., USA). The results were expressed as signal intensities nor-
malized to the respective   -actin or GAPDH signals.
 A  40 and A  42  ELISA of Cerebral A   
 The A  40 and A  42 quantities in the cortical soluble and in-
soluble fractions were determined using hA  40 and hA  42 ELISA 
kits according to the manufacturer’s instructions (The Genetics 
Company AG, Basel, Switzerland). Soluble fractions were normal-
ized to total cortical protein concentrations.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
6/
15
/2
01
6 
5:
53
:4
0 
PM
 Minocycline Increases Neurogenesis in 
APP/PS1 Mice 
Neurodegenerative Dis 2012;9:187–198 191
 Statistical Analyses 
 Statistical differences between groups were detected using, 
when appropriate, either one-way ANOVA followed by Bonfer-
roni post hoc test or the non-parametric Kruskal-Wallis test, fol-
lowed by pairwise comparisons using the Mann-Whitney U test. 
Spearman’s rank correlation coefficient (rho) was calculated to 
measure the statistical dependence of two variables. Data are pre-
sented as mean  8 SEM. Differences are considered significant at 
p  ! 0.05. Calculations were made with Statview 5.0.
 Results 
 Minocycline Reduces Microglia Activation in the 
Brain of APP/PS1 Mice 
 The doubly transgenic APP/PS1 mice used in our ex-
periments started to deposit A  plaques in cerebral cor-
tex and the CA1 region of the hippocampus at 2–3 months 
of age, consistent with previous findings  [30] . At 4 months 
of age, these mice exhibited compact A  plaques evenly 
scattered throughout the cortex and the outer molecular 
layer of the hippocampus, with approximately 1% of 
brain sections covered with A  . Treatment of 3-month-
old mice with minocycline for 6 weeks reduced the num-
bers of Iba+ microglia in the dentate gyrus by about 43%, 
attaining numbers of age-matched non-tg mice ( fig. 1 a, g, 
k). Merged overlays of triple-stained hippocampi show 
total microglia (Iba1 – green), intermediate- and amoe-
boid-like microglia over-expressing CD11b (CD11b – red) 
and astrocytes (GFAP – blue) in control-treated and mi-
nocycline-treated APP/PS1 mice ( fig. 1 j, n, respectively). 
We observed that remaining CD11b+ microglia were only 
present in the vicinity of A  deposits. Minocycline re-
duced the CD11b-immunoreactivity (IR) in these cells 
( fig. 1 b, h, l) in the hippocampus. A decline also seemed 
to occur in the cortical areas, but it did not reach statisti-
cal significance (APP/PS1: 0.07  8 0.03 APP/PS1 + mino-
cycline: 0.02  8 0.01% area, p = 0.17). Minocycline nor-
malized the increased hippocampal levels of the proin-
flammatory cytokines IL-6 and TNF-  ( fig.  1 d, e). 
Interestingly, these decreases were associated with a trend 
towards increased IL-10, an anti-inflammatory cytokine 
that can inhibit the synthesis of proinflammatory cyto-
kines ( fig. 1 f). Levels of IL-6 strongly correlated with the 
numbers of Iba1+ microglia, both in minocycline- and 
control-treated APP/PS1 mice ( fig. 1 c, rho = 0.88). Plasma 
levels of these cytokines were below detection limits. At 
3 months of age, microglia did not yet express MHC-II; 
MHC-II was detectable, however, in 11- to 12-month-old 
mice with more advanced A  pathology. Treatment
with minocycline did not alter the activation state of the 
remaining microglia as indicated by the unchanged rela-
tive frequencies of ramified, intermediate, amoeboid, 
and round Iba1+ cells ( table  1 ).  Minocycline did not
alter the numbers of GFAP+ astrocytes in the dentate gy-
rus ( fig. 1 i, m, and online supplementary figure S1, www.
karger.com/doi/10.1159/000330363).
 The iNOS releases NO solely in response to inflamma-
tion triggers. In the brain, iNOS is mainly induced in glia 
around sites of inflammation, e.g. A  plaques, and the 
production and release of NO by iNOS is associated with 
neuronal damage  [31] . Notably, following minocycline 
treatment the levels of iNOS in cortical homogenates 
were significantly reduced in APP/PS1 mice as compared 
to vehicle-treated APP/PS1 littermates, while the levels of 
iNOS in non-tg controls were below detection ( fig. 1 o, p). 
We were unable to detect differences in the levels of glio-
sis within the same treatment group associated with the 
stereotactic injections.
 Minocycline Protects Neurogenesis in the Absence of 
Reductions in A  Plaques 
 While blockade with minocycline of acute inflamma-
tion following lipopolysaccharide challenge improves the 
survival of newly born neurons  [13, 32] , the effects of mi-
nocycline on neurogenesis during the chronic neuroin-
flammation related to A  pathology are unknown. In 
3-month-old doubly transgenic mice, minocycline treat-
ment increased the numbers of BrdU+/NeuN+ mature 
neurons by 45% as compared to littermates that received 
vehicle (p = 0.0061;  fig.  2 ) and had significantly less 
BrdU+/NeuN+ cells than non-tg controls (p = 0.0014).
 Proliferating astrocytes, measured as numbers of 
BrdU+/S100  + cells, were not detectable in non-tg ani-
Table 1.  Relative frequencies (in %) of morphological phenotypes 
of Iba1+ microglia in non-tg and APP/PS1 doubly transgenic mice 
subjected to minocycline or vehicle administration
Ramified Inter-
mediate
Amoe-
boid
Round
Non-tg 8385 1685 0 0
Non-tg + minocycline 8086 1986 0.780.7 0
APP/PS1 6687 2784 785 0
APP/PS1 + minocycline 8387 1586 281 0
M orphological subtypes of Iba1+ microglia: ramified and in-
termediate represent quiescent and amoeboid and round repre-
sent activated microglia. No significant differences were observed 
between groups. Values are means + SEM; n = 5 per group.
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 Fig. 1.  a ,  b Minocycline treatment reduces 
microglia activation in APP/PS1 mice. The 
treatment reduced the numbers of Iba+ 
microglia in the dentate gyrus of APP/
PS1 mice to non-tg controls levels as well 
as decreased CD11b-immunoreactivity 
(IR) in the hippocampus of APP/PS1 mice. 
 d ,  e Minocycline did not significantly re-
duce the levels of TNF-  , but downregu-
lated the concentrations of IL-6 (p = 0.06). 
 f The anti-inflammatory treatment was 
also associated with higher levels of the an-
ti-inflammatory cytokine IL-10 (p = 0.07), 
(n = 5 per group/cytokine).  c  The number 
of Iba1+ microglia positively correlated 
with levels of IL-6.  g–n Photomicrographs 
of immunofluorescent triple-labeled hip-
pocampi show total microglia (Iba1 – 
green), activated microglia (CD11b – red), 
astrocytes (GFAP – blue) and respective 
overlay for APP/PS1 ( g–j ), and for APP/
PS1 minocycline-treated mice ( k–n ).  In-
sets in  h and  l represent high-magnifica-
tion details of CD11b+ microglia selected 
by the yellow squares.  o Western blot anal-
ysis of cortical samples to measure the lev-
els of inflammation-driven protein iNOS 
in non-tg and APP/PS1 animals (middle 
lane). The same blot was then reprobed 
with anti-  amyloid antibody 6E10 to con-
firm the presence of the human APP trans-
gene in these samples (upper lane). Equal 
protein loadings were confirmed by mea-
suring GAPDH (lower lane). There was a 
significant decrease in densitometric val-
ues of iNOS protein in brain homogenates 
of APP/PS1 mice treated with minocy-
cline. Scale bars = 60   m ( g–n ) and 5   m 
( insets ). Dashed lines depict the SGZ. 
OML = Outer molecular layer. Error bars 
represent SEM.  *   p  ! 0.05,  * *   p  ! 0.01, 
ANOVA followed by Bonferroni post hoc 
test, Mann-Whitney U test and Spearman 
correlation. 
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mals, and did not differ between minocycline- and vehi-
cle-treated transgenic mice (p = 0.58, online suppl. figure 
S2A). Also, no significant differences were detected be-
tween the groups in numbers of Ki67+ cells (p = 0.65, on-
line suppl. figure S2B), DCX+ neuroblasts (p = 0.64, on-
line suppl. figure S2C), or PCNA+/DCX+ cells (p = 0.77, 
online suppl. figure S2D).
 Taken together, these data provide evidence that mi-
nocycline prevented the death of the newly born neurons 
in APP/PS1 mice without affecting cell proliferation or 
progenitors’ fate choice.
 We next verified whether minocycline treatment 
could affect amyloid levels in the brain of the transgenic 
animals. The spatial accumulation of A  pathology was 
estimated by the detection of A  by ThioS and 6E10. De-
position of A  was unaltered among treatment and pla-
cebo groups ( fig. 3 a–e). Measurement of the respective 
levels of A  40 and A  42 in the cortical soluble and in-
soluble extracts did not reveal any difference among 
treatment groups ( fig. 3 f, g). Although not reaching sta-
tistical significance, mean levels of soluble A  40 and in-
soluble A  42 were higher in minocycline-treated APP/
PS1 mice (p = 0.35 and 0.25, respectively). Whether lon-
ger anti-inflammatory treatment would have lead to 
higher levels of A  , in support of a role for activated mi-
croglia in the clearance of A  in APP/PS1 mice, awaits 
further studies. To exclude an effect of minocycline on 
the different A  species, the levels of monomeric A  
were determined by Western blot assay but no differenc-
es among groups were detected ( fig. 3 h, i). Monomeric 
A  was also analyzed by Western blot of the insoluble 
extracts, and no differences were found between groups 
(data not shown). Together these results show that mino-
cycline promoted the survival of newly born neurons 
without reducing A  pathology and reversing the mor-
phological deficits of newly born neurons associated 
with A  -related toxicity.
 To analyze the detailed morphology of the new gran-
ule cells, we labeled them using hippocampal injection of 
GFP-expressing retroviral vector and imaged them in a 
3-dimensional manner. We found that, despite the in-
crease in the number of newly-born neurons in minocy-
cline-treated mice, the A  -related morphological deficits 
were still present during minocycline treatment consis-
tent with the persisting A  pathology in the treated mice. 
Scholl analyses to quantify the extent of dendritic branch-
ing at increasing distances from the cell body indicated 
GFP+ mature new neurons with significantly less den-
dritic arborization and shorter processes than non-tg 
equivalents in both vehicle- and minocycline-treated 
groups ( fig.  4 a, b). Moreover, the classification of den-
dritic spines according to the Peters and Kaiserman-
a b c d
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 Fig. 2. Minocycline increases numbers of newly-born neurons in 
APP/PS1 mice.  a–d Neurogenesis in the dentate gyrus of non-tg 
mice: non-tg minocycline treated ( a ), APP/PS1 vehicle- ( b ), and 
minocycline-treated mice ( c ); detected by double immunofluo-
rescence for NeuN (blue) and BrdU (red) ( d ).  e–h Representative 
high magnification photomicrographs and orthogonal projection 
of confocal images of the area depicted by the yellow square in  d 
confirmed the colocalization of the double-staining BrdU/NeuN. 
 i Minocycline administration resulted in restored numbers of 
BrdU+/NeuN+ new granular neurons. Scale bars = 120   m ( a ), 20 
  m ( e ). Error bars represent SEM.  * *  p  ! 0.01 ANOVA followed 
by Bonferroni post hoc test. 
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Abramof classification  [33] indicated loss of mushroom 
and stubby spines ( fig. 4 c–e) but no differences in num-
bers of long-thin spines ( fig. 4 c, f).
 Minocycline Restores Recognition Memory 
 Because minocycline treatment stimulated neurogen-
esis, we next tested the hypothesis that minocycline could 
also improve cognitive deficits in APP/PS1 mice. To this 
aim, we adopted a delayed non-matching-to-sample test, 
a paradigm based on the tendency of rodents to explore 
more a novel object than a familiar one  [34] . Recognition 
of the familiar object, and consequent increased interac-
tion with the new one, requires intact neural processes 
mediating storage and/or subsequent recall of the fea-
tures of the familiar object  [23] . Mounting evidence indi-
cates that these neural circuits may benefit from adult 
neurogenesis  [35–38] . We tested all mice after 6-week 
treatments with minocycline compared to vehicle in a 
blinded design. Mice were first exposed for 5 min to an 
object, the familiar object, followed 20 min later by expo-
sure to a novel object presented together with the familiar 
object. Vehicle-treated APP/PS1 mice failed to recognize 
the familiar object, spending less amount of time explor-
ing the novel one, indicating recognition memory im-
e
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 Fig. 3. Minocycline does not alter A  pa-
thology in APP/PS1 mice.  a–d Spatial ac-
cumulation of A  plaques was not affected 
by minocycline treatment in APP/PS1. 
ThioS staining of compact A  and 6E10 
staining of diffuse A  did not differ be-
tween APP/PS1 vehicle- ( a ,  c ) and minocy-
cline-treated mice ( b ,  d ).  e Quantification 
of the brain area covered by ThioS or 
6E10 did not detect any changes, regard-
less of the treatment.  f ,  g Respective con-
centrations of A  40 and A  42 in soluble ( f ) 
and insoluble ( g ) cortical extracts showed 
no differences among treatment groups. 
 h ,  i Representative 6E10 immunoblot from 
soluble cortical homogenates minocy-
cline-administration had no effect on mo-
nomeric A  species ( h ), as quantified by 
densitometric analysis of A  signal inten-
sity normalized to   -actin ( i ). Error bars 
represent SEM. Scale bar = 0.9 mm ( a ). 
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pairment. Minocycline rescued this phenotype to levels 
of non-tg control mice ( fig. 5 a). The average times spent 
interacting with the objects A and B during the novelty 
phase are shown in  figure 4 b. To determine whether the 
mice discriminate between familiar and novel objects, 
the exploration ratios obtained under each condition 
were compared with the expected 0.5 chance ratio using 
one-sample t tests. Non-tg mice, as well as minocycline-
treated APP/PS1, had exploration ratios that were signif-
icantly above the chance level (t = 3.483, p = 0.04 and t = 
3.945, p = 0.0056, respectively), whereas vehicle-treated 
APP/PS1 mice did not differ from chance level (t = 2.055, 
p = 0.17 and t = –1.689, p = 0.1665, respectively). The treat-
ment with minocycline had no effect on the locomotor 
activity nor on the number of rearings (data not shown). 
Also, there was no difference between groups in the Y-
maze, a working memory paradigm (non-tg: 59.73  8 
4.79% vs. non-tg + minocycline: 63.48  8 3.25% vs. APP/
PS1: 65.34  8 2.66% vs. APP/PS1 + minocycline: 64.99  8 
3.36%, percentage of alternations).
 Discussion 
 The aim of the present study was to determine the ef-
fect of microglia inflammation on adult hippocampal 
neurogenesis in an AD mouse model with early onset of 
plaque deposition. We demonstrated that the treatment 
of APP/PS1 mice with the anti-inflammatory tetracycline 
derivative minocycline significantly reduced the num-
bers of microglia in the dentate gyrus as well as the im-
munoreactivity of activated microglia and the levels of 
the inflammation-induced protein iNOS. The reduction 
in microglial activation was accompanied by a significant 
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 Fig. 4. Minocycline does not rescue den-
dritic atrophy and loss of spines in APP/
PS1 mice.  a Scholl analysis of mature new 
granular cells labeled with a retroviral vec-
tor expressing GFP revealed loss of den-
dritic complexity in APP/PS1 mice com-
pared to non-tg mice, regardless of the 
treatment. The graph represents the mean 
number of intersections between den-
drites and concentric radii, centered at the 
cell body, as a function of distance from 
the soma, n = 10 cells per group.  b Repre-
sentative confocal pictures of GFP+ ma-
ture new neurons for the three groups in 
study. Computer-assisted classification of 
spines along 40-  m segments did not de-
tect difference in the number of ‘long-thin’ 
spines among groups ( c ); however, the 
analysis reported lower numbers of ‘mush-
room’ spines ( d ) and ‘stubby’ spines ( e ) in 
APP/PS1 mice, both vehicle- and minocy-
cline-treated, compared to non-tg (n = 25 
segments per group).  f Selected high-mag-
nification segments from respectively 
non-tg, APP/PS1 vehicle- and minocy-
cline-treated mice. Scale bars = 60   m ( b ), 
5   m ( f ). Error bars represent SEM.  *  p  ! 
0.05,  * *   p  ! 0.001, ANOVA followed by 
Bonferroni post hoc test. 
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increase in numbers of mature newly formed (BrdU+/
NeuN+) neurons in the SGZ/GCL, suggesting a protec-
tive role for minocycline on the survival of new granule 
cells. Minocycline neither reduced the A  load in the 
brains of the transgenic mice nor did it restore the mor-
phological deficits and loss of spines in GFP+ new neu-
rons. However, minocycline-treated transgenic mice 
scored significantly higher in a hippocampus-dependent 
object recognition test: APP/PS1 without treatment 
showed a severe impairment in this test, whereas APP/
PS1 mice that received minocycline performed compara-
bly to non-tg mice.
 APP/PS1 doubly transgenic mice develop A  pathol-
ogy accompanied by a strong inflammatory response  [6] . 
Inflammation as a result of A  pathology may be in-
volved in driving disease progression and neurodegen-
eration  [5, 39] . Therefore, anti-inflammatory drugs are 
being tested in clinical trials, however, with contradic-
tory results obtained so far  [40] . Consistent with our re-
sults, two independent studies with different transgenic 
mouse models indicated that reduction of microglia acti-
vation with minocycline improved cognition in the pres-
ence of unchanged A  burden  [14, 18] . Our results are in 
line with these interpretations, and raise the possibility 
that minocycline-induced rescue of neurogenesis con-
tributes to this effect.
 On the other hand, Ziv et al.  [41] reported that hippo-
campal neurogenesis induced by an enriched environ-
ment was associated with both the recruitment of T cells 
and the activation of microglia, and that it was accompa-
nied by improved spatial learning abilities. Moreover, fa-
milial AD-causing PS1 mutations expressed in microglia 
blocked enriched environment-related hippocampal pro-
genitor cell proliferation and differentiation  [42] . Togeth-
er, these and our results suggest that microglia can sup-
port neurogenesis in certain conditions while blocking it 
in others, most likely in dependence on their molecular 
phenotype. Here we found that minocycline-evoked at-
tenuation of microglia activation, resulting from A  pa-
thology, protects neurogenesis. Similar data, noteworthy 
in the presence of both astro- and micro-gliosis ablation, 
were reported in another study where vector-mediated 
overexpression of an anti-inflammatory cytokine in the 
brain of APP/PS1 bigenic mice resulted in attenuation of 
AD-like pathology, improved behavior, and increased 
neurogenesis  [43] . In accordance, minocycline changed 
the cytokine profile in our animals from proinflamma-
tory to anti-inflammatory indicated by decreased TNF  
and IL-6 and possibly increased IL-10 levels  [32, 44, 45] .
 Although not reaching statistical significance, mino-
cycline treatment showed a tendency to reduce adult neu-
rogenesis in non-tg animals (about 40% less BrdU+/
NeuN+ cells than non-tg vehicle-treated littermates). In-
terestingly, Noble et al.  [46] observed a detrimental effect 
of minocycline on non-tg animals: minocycline de-
creased tau phosphorylation and aggregation in tau 
transgenic mice, but increased tau phosphorylation in 
non-tg mice treated with minocycline. Although this ob-
servation awaits further studies, they suggested that dif-
ferent targets of minocycline may be differently affected 
depending upon the distinctive up-regulation of their 
pathways. In agreement with a possible dual role of the 
treatment, minocycline was reported to have different ef-
fects at different ages of the same transgenic AD mouse 
model  [18] . These data could also partially explain why, 
in spite of a plethora of successful trials at the laboratory 
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 Fig. 5. Minocycline treatment restores hip-
pocampus-dependent memory deficits in 
APP/PS1 mice as assessed in a recognition 
memory task. Behavioral testing was done 
after 6 weeks of daily treatment with mi-
nocycline.  a Object recognition perfor-
mance of APP/PS1 minocycline-treated 
was significantly better than that of APP/
PS1 vehicle-treated and it was comparable 
to that of non-tg controls. Object recogni-
tion index was calculated as the ratio ( T B 
 * 100)/( T A +  T B), where  T A and  T B are the 
time spent during the second exposure on 
object A and object B, respectively.  b The 
average  T A and  T B per group. Error bars 
represent SEM.  *   p  ! 0.05, ANOVA fol-
lowed by Bonferroni post hoc test. 
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scale, minocycline never succeeded at passing clinical tri-
als  [40] .
 Our results support a detrimental action of proin-
flammatory microglia on adult hippocampal neurogen-
esis in transgenic mice expressing familial AD-causing 
APP and PS1 mutations. We have previously shown that 
A  immunotherapy promotes the survival of newly born 
neurons in APP/PS1 mice and restores their dendrite 
branching and spine density  [22] . Here, we found that 
downregulation of neuroinflammation leads to in-
creased survival of new neurons. In contrast, we did not 
detect any improvements in the morphology or spine 
numbers of newly born neurons following minocycline 
treatment. This result may be explained by the un-
changed A  burden, known to affect synaptic functions 
leading to the disruption of the neural networks  [47] . 
Whether the combination of A  immunotherapy and 
anti-inflammatory treatment can result in additive im-
provement of hippocampal regeneration in AD mouse 
models, including the functional integration of the new 
neurons in the pathological environment  [48] , awaits 
further studies.
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